Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="center" colspan="4">Complications</td></tr><tr class="thead"><td align="left">Grade 1-2</td><td align="center">Grade 3</td><td align="center">Grade 4</td><td align="center">Grade 5</td></tr><tr class="thead"><td align="left"><svg height="11.3125" id="M9" style="vertical-align:-0.1092pt" version="1.1" viewbox="0 0 42.5625 11.3125" width="42.5625" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.113)"><use xlink:href="#x1D441"></use></g><g transform="matrix(.017,-0,0,-.017,19.628,11.113)"><use xlink:href="#x3D"></use></g><g transform="matrix(.017,-0,0,-.017,34.332,11.113)"><use xlink:href="#x34"></use></g>
</svg> (4.9%)</td><td align="center"><svg height="11.375" id="M10" style="vertical-align:-0.1638pt" version="1.1" viewbox="0 0 42.5625 11.375" width="42.5625" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><path d="M857 650l-6 -28q-44 -4 -61.5 -16.5t-29.5 -48.5q-11 -32 -37 -166l-78 -399h-29l-351 537h-4l-56 -276q-24 -120 -24 -164q0 -35 17.5 -46t75.5 -15l-6 -28h-245l7 28q41 2 62 14t31 44q10 30 41 171l53 245q8 44 6.5 60.5t-14.5 33.5q-10 15 -27 19.5t-64 6.5l6 28h153
l350 -516h5l48 257q25 131 25 171q0 34 -17.5 45t-77.5 15l7 28h240z" id="x1D441"></path></g><g transform="matrix(.017,-0,0,-.017,19.628,11.112)"><path d="M535 323h-483v50h483v-50zM535 138h-483v50h483v-50z" id="x3D"></path></g><g transform="matrix(.017,-0,0,-.017,34.332,11.112)"><path d="M249 635q70 0 116 -43t46 -105q0 -46 -28 -80q-22 -25 -80 -64q62 -35 97 -75t35 -99q0 -81 -63 -131t-135 -50q-83 0 -137.5 45.5t-54.5 123.5q0 52 45 95q29 28 89 64q-109 62 -109 155q0 66 50.5 115t128.5 49zM238 603q-42 0 -67.5 -31t-25.5 -72q0 -50 32.5 -79.5
t98.5 -62.5q61 48 61 124q0 59 -29.5 90t-69.5 31zM248 20q46 0 76.5 33.5t30.5 89.5q0 50 -39 85.5t-110 71.5q-81 -54 -81 -137q0 -67 35.5 -105t87.5 -38z" id="x38"></path></g>
</svg> (9.8%)</td><td align="center"><svg height="11.425" id="M11" style="vertical-align:-0.20474pt" version="1.1" viewbox="0 0 42.5625 11.425" width="42.5625" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><use xlink:href="#x1D441"></use></g><g transform="matrix(.017,-0,0,-.017,19.628,11.112)"><use xlink:href="#x3D"></use></g><g transform="matrix(.017,-0,0,-.017,34.332,11.112)"><path d="M244 635q90 0 143 -72t53 -177q0 -133 -65 -229.5t-171 -139.5q-79 -32 -140 -32l-5 30q109 18 185 91t101 186l-68 -36q-29 -16 -60 -16q-79 0 -129 51.5t-50 130.5q0 80 57 146.5t149 66.5zM228 602q-52 0 -78 -45.5t-26 -98.5q0 -69 36.5 -115.5t97.5 -46.5
q53 0 90 28q4 31 4 66q0 51 -9.5 95.5t-39 80.5t-75.5 36z" id="x39"></path></g>
</svg> (11.0%)</td><td align="center"><svg height="11.375" id="M12" style="vertical-align:-0.1638pt" version="1.1" viewbox="0 0 42.5625 11.375" width="42.5625" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><use xlink:href="#x1D441"></use></g><g transform="matrix(.017,-0,0,-.017,19.628,11.112)"><use xlink:href="#x3D"></use></g><g transform="matrix(.017,-0,0,-.017,34.332,11.112)"><path d="M285 378v-2q65 -13 102 -54.5t37 -97.5q0 -57 -30.5 -104.5t-74 -75t-85.5 -42t-72 -14.5q-31 0 -59.5 11t-40.5 23q-19 18 -16 36q1 16 23 33q13 10 24 0q58 -51 124 -51q55 0 88 40t33 112q0 64 -39 96.5t-88 32.5q-29 0 -64 -11l-6 29q77 25 118 57.5t41 84.5
q0 45 -26.5 69.5t-68.5 24.5q-67 0 -120 -79l-20 20l43 63q51 56 127 56h1q66 0 107 -37t41 -95q0 -42 -31 -71q-22 -23 -68 -54z" id="x33"></path></g>
</svg> (3.7%)</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">Minor leakage: 2</td><td align="center">Pancreas fistula: 2</td><td align="center">Renal failure: 3</td><td align="center">MOF from leakage: 3</td></tr><tr><td align="left"></td><td align="center">Major leakage: 4</td><td align="center">Major leakage: 4</td><td align="center"></td></tr><tr><td align="left">Abd. wall dehiscence: 1</td><td align="center">Abdominal bleeding: 1</td><td align="center">Bleeding: 1</td><td align="center"></td></tr><tr><td align="left">Abdominal abscess: 1</td><td align="center">Port infection: 1</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

International Journal of Surgical Oncology

tab5

Table 5

Table 5: Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer 

Table 5 | Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer 